<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-id journal-id-type="iso-abbrev">Br. J. Cancer</journal-id><journal-title-group><journal-title>British Journal of Cancer</journal-title></journal-title-group><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28441381</article-id><article-id pub-id-type="pmc">5520096</article-id><article-id pub-id-type="pii">bjc2017117</article-id><article-id pub-id-type="doi">10.1038/bjc.2017.117</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Study</subject></subj-group></article-categories><title-group><article-title>Text-message Reminders in Colorectal Cancer Screening (TRICCS): a randomised
controlled trial</article-title><alt-title alt-title-type="running">Text Reminders in Colorectal Cancer Screening</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hirst</surname><given-names>Yasemin</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Skrobanski</surname><given-names>Hanna</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kerrison</surname><given-names>Robert S</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kobayashi</surname><given-names>Lindsay C</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Counsell</surname><given-names>Nicholas</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Djedovic</surname><given-names>Natasha</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Ruwende</surname><given-names>Josephine</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Stewart</surname><given-names>Mark</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>von Wagner</surname><given-names>Christian</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="caf1">*</xref></contrib><aff id="aff1"><label>1</label><institution>The Research Department of Behavioural
Science and Health, University College London</institution>, Gower
Street, London
WC1E 7BT, <country>UK</country></aff><aff id="aff2"><label>2</label><institution>Center for Population and Development
Studies, Harvard T. H. Chan School of Public Health, Harvard University</institution>,
Cambridge, MA
02138, <country>USA</country></aff><aff id="aff3"><label>3</label><institution>Cancer Research UK &#x00026; UCL Cancer
Trials Centre, Cancer Institute, University College London</institution>, 90
Tottenham Court Road, London
W1T 4TJ, <country>UK</country></aff><aff id="aff4"><label>4</label><institution>St Marks Bowel Cancer Screening Centre,
St Marks Hospital</institution>, Watford Road, Harrow,
Middlesex
HA1 3UJ, <country>UK</country></aff><aff id="aff5"><label>5</label><institution>NHS England London Region,
Southside</institution>, 105 Victoria Street, London
SW1E 6QT, <country>UK</country></aff></contrib-group><author-notes><corresp id="caf1"><label>*</label>E-mail: <email>c.wagner@ucl.ac.uk</email></corresp></author-notes><pub-date pub-type="ppub"><day>23</day><month>05</month><year>2017</year></pub-date><pub-date pub-type="epub"><day>25</day><month>04</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>23</day><month>5</month><year>2017</year></pub-date><volume>116</volume><issue>11</issue><fpage>1408</fpage><lpage>1414</lpage><history><date date-type="received"><day>28</day><month>11</month><year>2016</year></date><date date-type="rev-recd"><day>21</day><month>02</month><year>2017</year></date><date date-type="accepted"><day>05</day><month>04</month><year>2017</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2017 The Author(s)</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>The Author(s)</copyright-holder><license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><!--author-paid--><license-p>This work is licensed under the Creative Commons Attribution 4.0
International License. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link></license-p></license></permissions><abstract><sec><title>Background:</title><p>We investigated the effectiveness of a text-message reminder to improve uptake of
the English Bowel Cancer Screening programme in London.</p></sec><sec><title>Methods:</title><p>We performed a randomised controlled trial across 141 general practices in London.
Eight thousand two hundred sixty-nine screening-eligible adults (aged 60&#x02013;74
years) were randomised in a 1&#x02009;:&#x02009;1 ratio to receive either a
text-message reminder (<italic>n</italic>=4134) or no text-message reminder
(<italic>n</italic>=4135) if they had not returned their faecal occult blood
test kit within 8 weeks of initial invitation. The primary outcome was the
proportion of adults returning a test kit at the end of an 18-week screening
episode (intention-to-treat analysis). A subgroup analysis was conducted for
individuals receiving an invitation for the first time.</p></sec><sec><title>Results:</title><p>Uptake was 39.9% in the control group and 40.5% in the intervention
group. Uptake did not differ significantly between groups for the whole study
population of older adults (adjusted odds ratio (OR) 1.03, 95% confidence
interval (CI) 0.94&#x02013;1.12; <italic>P</italic>=0.56) but did vary between the
groups for first-time invitees (uptake was 34.9% in the control and
40.5% in the intervention; adjusted OR 1.29, 95% CI 1.04&#x02013;1.58;
<italic>P</italic>=0.02).</p></sec><sec><title>Conclusions:</title><p>Although text-message reminders did not significantly increase uptake of the
overall population, the improvement among first-time invitees is encouraging.</p></sec></abstract><kwd-group><kwd>colorectal</kwd><kwd>cancer screening</kwd><kwd>randomised controlled trial</kwd><kwd>reminder</kwd><kwd>uptake</kwd><kwd>text-message</kwd></kwd-group></article-meta></front><body><p>Colorectal cancer (CRC) is the fourth most common cancer and the second leading cause of
cancer death in the United Kingdom (<xref ref-type="bibr" rid="bib3">Cancer Research UK,
2016a</xref>, <xref ref-type="bibr" rid="bib4">b</xref>). In England, the National Health
Service (NHS) runs the Bowel Cancer Screening Programme (BCSP), an organised CRC
screening programme that offers biennial guaiac faecal occult blood testing (gFOBt) to
men and women aged 60&#x02013;74 years. Screening is widely recommended for the early
detection of CRC and repeated participation in CRC screening has been shown to reduce
CRC mortality by up to 25% (<xref ref-type="bibr" rid="bib27">Scholefield <italic>et al</italic>,
2002</xref>; <xref ref-type="bibr" rid="bib9">Hewitson <italic>et al</italic>, 2008</xref>; <xref ref-type="bibr" rid="bib18">Levin <italic>et al</italic>, 2008</xref>; <xref ref-type="bibr" rid="bib30">Sung <italic>et
al</italic>, 2015</xref>). However, overall uptake of CRC screening in England is
low at approximately 56% (<xref ref-type="bibr" rid="bib11">House of Commons,
2014</xref>).</p><p>Commonly reported reasons for non-participation in CRC screening include forgetting or
not getting around to completing the test kit and being too busy (<xref ref-type="bibr" rid="bib15">Janz <italic>et al</italic>, 2007</xref>; <xref ref-type="bibr" rid="bib32">van Rijn <italic>et al</italic>,
2008</xref>; <xref ref-type="bibr" rid="bib31">van Dam <italic>et al</italic>, 2013</xref>; <xref ref-type="bibr" rid="bib21">Lo <italic>et al</italic>, 2015b</xref>). Previous studies have shown that
various modalities of reminders are effective at improving CRC screening uptake,
including telephone and postal reminders (<xref ref-type="bibr" rid="bib2">Baron <italic>et al</italic>,
2008</xref>; <xref ref-type="bibr" rid="bib26">Power <italic>et al</italic>, 2009</xref>; <xref ref-type="bibr" rid="bib5">Camilloni <italic>et al</italic>, 2013</xref>). Telephone reminders have been
found to be the most effective reminder modality, improving CRC screening uptake by up
to 21% (<xref ref-type="bibr" rid="bib24">Myers <italic>et al</italic>, 2007</xref>; <xref ref-type="bibr" rid="bib28">Segnan <italic>et al</italic>, 2010</xref>; <xref ref-type="bibr" rid="bib5">Camilloni
<italic>et al</italic>, 2013</xref>; <xref ref-type="bibr" rid="bib6">Davis <italic>et al</italic>,
2014</xref>). However, the cost of telephone reminders is often prohibitive in the
context of publicly funded screening programmes due to the additional labour they
require (<xref ref-type="bibr" rid="bib28">Segnan <italic>et al</italic>, 2010</xref>).</p><p>In the United States, a randomised controlled trial (RCT) examining the effectiveness of
a multicomponent strategy to increase uptake of gFOBt through community health centres
found that text-messages (also referred to as Short Messaging Service), when used in
conjunction with postal and automated telephone reminders, achieved uptake of
82%, compared with 37% in the usual care group (<xref ref-type="bibr" rid="bib1">Baker
<italic>et al</italic>, 2014</xref>). In the context of organised screening in the
United Kingdom, two recent studies found that preappointment text-message reminders were
effective at increasing attendance at routine breast screening appointments (<xref ref-type="bibr" rid="bib12">Icheku and Arowobusoye, 2015</xref>; <xref ref-type="bibr" rid="bib17">Kerrison
<italic>et al</italic>, 2015</xref>). The effectiveness of text-message reminders to
promote uptake of gFOBt in the NHS BCSP, however, has not been examined (<xref ref-type="bibr" rid="bib29">Senore <italic>et al</italic>, 2015</xref>). Unlike preappointment reminders
for the NHS Breast Screening Programme, a reminder for CRC screening in the BCSP would
act as an additional prompt to complete and return a gFOBt kit beyond the standard
4-week postal reminder (<xref ref-type="bibr" rid="bib8">Halloran, 2009</xref>).</p><p>Text-messages are often considered to be the next best alternative to telephone
reminders, as they have the advantage of providing instant and direct transmission at a
low cost (<xref ref-type="bibr" rid="bib7">Gurol&#x02013;Urganci <italic>et al</italic>, 2013</xref>). They
also have an advantage over postal reminders, as the direct transmission of
text-messages to a person&#x02019;s mobile phone means they are unlikely to be misplaced
as items sent through the post (<xref ref-type="bibr" rid="bib16">Kaplan, 2006</xref>). The
effectiveness of delivering text-messages is likely to be influenced by mobile phone
coverage and the accuracy of mobile phone records in the clinical systems. Mobile
technology has the potential to provide outreach and access to people regardless of
socioeconomic status, race, ethnicity, or location, with 93% of the UK population
personally owning or using a mobile phone (<xref ref-type="bibr" rid="bib25">Ofcom, 2016</xref>).
However, challenges with integrating mobile technology with primary care remain, as a
recent study reported that only 39.8% of the eligible population had a registered
mobile on their GP&#x02019;s clinical system (<xref ref-type="bibr" rid="bib17">Kerrison <italic>et
al</italic>, 2015</xref>).</p><p>The effect of a text-message reminder for CRC screening is likely to be different based
on an individual&#x02019;s history with the screening programme, specifically whether they
are first-time or repeat invitees in a given screening round. Uptake at first-time
invitation is the strongest predictor of repeat uptake in the second round of
invitations. A recent population-based study showed that uptake of the second round of
invitations was 87% among people who previously participated in the first round
(<xref ref-type="bibr" rid="bib20">Lo <italic>et al</italic>, 2015a</xref>). In comparison, uptake
among people invited for CRC screening for the first time is only around 54%
(<xref ref-type="bibr" rid="bib33">von Wagner <italic>et al</italic>, 2011</xref>). Furthermore, a
recent series of trials piloting interventions to improve uptake of the BCSP in England
found that interventions had a significantly stronger impact among first-time invitees
compared with those who had previously been invited (<xref ref-type="bibr" rid="bib34">White <italic>et
al</italic>, 2015</xref>). Thus there is greater opportunity to promote uptake
among first-time invitees, which would lead to greater future adherence among
screening-eligible adults.</p><p>The primary aim of this RCT was to test the effectiveness of a text-message reminder to
increase gFOBt uptake. The outcome measure was the total proportion of invitees
adequately screened 18 weeks after the initial invitation was sent. Our secondary aims
were to examine whether or not a text-message reminder is more effective in improving
uptake among first-time invitees than repeat invitees and to establish the efficacy of
the text-messages by testing the effectiveness among the non-responders who also had a
registered mobile number. The findings will be important to show the impact of the
intervention on the overall population and also the subgroups who are of interest of the
text-message reminder intervention.</p><sec><title>Methods and materials</title><sec><title>Study design and setting</title><p>We performed a two-arm RCT in London across six Clinical Commissioning Groups
((CCGs): NHS organisations that manage patient care in GPs in defined geographical
areas): Croydon, Greenwich, Hammersmith and Fulham, Hounslow, Lewisham, and West
London. The study was carried out in collaboration with the NHS Bowel Cancer
Screening Hub in London (hereafter referred to as &#x02018;the hub&#x02019;), who were
responsible for creating and maintaining the study database, and iPlato (<xref ref-type="bibr" rid="bib13">iPlato, 2013</xref>), who were responsible for randomising
eligible adults and delivering the text-message reminders. iPlato is an NHS
Information Governance approved mobile health (m-health) organization, which
provides patient care messaging services to primary and secondary health care in
England.</p><p>From age 60 and up to age 74 years, the NHS BCSP biennially invites all men and
women take part in CRC screening using the gFOBt kit. The gFOBt pathway includes a
baseline invitation to initiate a screening episode, which is characterised as an
18-week-long period for the adequate completion of a gFOBt kit. A week after the
initial invite, the kit is dispatched, and a reminder is sent out on the fifth
week of the initial invite if the kit had not been returned. Unless the results
are abnormal, CRC screening does not include further investigations beyond the
gFOBt pathway.</p><p>In this two-arm trial, individuals who were randomly allocated to the control
group were invited to take part in the BCSP as per the usual care pathway, while
individuals randomly allocated to the intervention group were additionally sent a
text-message reminder if they had not returned their test kit 7 weeks into their
screening episode and had a mobile number stored on their GP&#x02019;s clinical
system (see <xref ref-type="fig" rid="fig1">Figure 1</xref>).</p><p>Further details of the intervention design and procedures for this RCT are
available in the published protocol (<xref ref-type="bibr" rid="bib10">Hirst <italic>et al</italic>,
2016</xref>).</p></sec><sec><title>GP recruitment</title><p>All GPs situated within the six CCGs were emailed and invited to participate in
this study between November and December 2015. This invitation was followed by
weekly email reminders. Practices were eligible if they already had an existing
patient messaging service, which ensured patient consent for text-messages. In
order to facilitate automated text-messages, all practices had to connect to the
study-specific iPlato server, irrespective of their routine m-health provider in
use for text-messages. In total, 144 out of 295 practices (48.8%) agreed to
take part and returned their consent forms. Owing to technical difficulties, only
141 out of 144 GPs were successfully connected to iPlato. Low response rate was
considered to be an outcome of the eligibility criteria (<xref ref-type="bibr" rid="bib10">Hirst <italic>et al</italic>, 2016</xref>).</p></sec><sec><title>Trial procedures</title><sec><title>Identification</title><p>Between January and March 2016, the hub retrospectively identified all men and
women aged 60&#x02013;74 years from all 141 practices to be included in the study
based on the start date of their gFOBt screening episode. Each week, everyone
who had been invited 7 weeks back were included, irrespective of whether or not
they had already completed and returned their faecal occult blood test kit.</p><p>The Hub then transferred the list of the screening adults to iPlato. The weekly
file contained relevant data to the individuals&#x02019; screening statuses,
including their unique identifier used within the NHS, referred to as the
&#x02018;NHS Number&#x02019;, the kit return status (Yes/No), the date of
screening invitation (Date/Month/Year) used to calculate the date of a
text-reminder, and GP code for tailored text-messages (a unique GP
identifier).</p></sec><sec><title>Data processing and generation</title><p>On receipt of the data at iPlato, individuals were randomised each week in a
1&#x02009;:&#x02009;1 ratio to either the intervention or control condition.
Randomisation was conducted using Mersenne Twister: a computerised,
pseudorandom number generator (<xref ref-type="bibr" rid="bib22">Matsumoto and Nishimura,
1998</xref>).</p><p>After randomisation, registered mobile number status (Yes/No) was added to
the weekly data file, as well as delivery status of the text-message reminder
(Yes/No) if the person was in the intervention group and eligible to
receive a text-message. The last text-message reminder was sent on the 18 March
2016. When the last of the individual screening episodes were closed 18 weeks
after the delivery of the baseline FOBt invitation, a complete data set was
returned via secure email transfer to the Hub.</p></sec><sec><title>Data merge and anonymisation</title><p>The Hub made a record of whether or not a gFOBt had been adequately completed
by the individual within the study database and then added individual-level
data on age, gender, the name of the CCG, the screening episode sequence number
(i.e., the number of screening test kits received by the eligible individual),
and area-level of deprivation (i.e., derived from the &#x02018;Index of Multiple
Deprivation&#x02019; (IMD) score) to the data set. The IMD uses census-derived
indicators of income, education, employment, living environment, health and
disability, barriers to housing and services, and crime at small-area level to
generate a scale from 0 (least deprived) to 80 (most deprived). For the
purposes of our analysis, IMD scores were categorised into quintiles of the
national distribution to enable comparisons between individuals living in the
most and least deprived groups of areas to be made. Prior to transferring to
the research team for analysis, the Hub additionally removed identifiable data
(e.g., NHS number, GP code, and postcode), which had been used to facilitate
the research.</p></sec></sec><sec><title>Trial registration and ethics</title><p>The study was approved by the East Midlands National Research Ethics Service
(15/EM/0159) and is registered with the International Standard Randomised
Controlled Trial Number (ISRCTN) registry for transparency (ISRCTN70904476
(18/09/2015)). The study has also been reviewed by the Confidentiality
Advisory Group (CAG) and granted full approval (15/CAG/0156), permitting
iPlato to process identifiable information for the purposes of this study to be
able to send automated text-messages from participating GPs.</p></sec><sec><title>Statistical analysis</title><p>The characteristics of the screening-eligible population were demonstrated using
descriptive statistics. The primary study outcome, the proportion of invitees who
returned a test kit within 18 weeks, was assessed on an intention-to-treat basis.
A subgroup analysis using interaction terms were included to test the intervention
by invitation status (first-time invitee=0; repeat invitee=1). The
invitation status variable was computed by dichotomising the screening episode
sequence number. A secondary analysis was also performed, restricting the sample
to individuals who had not returned their kit within 8 weeks and had a registered
mobile number on their GP&#x02019;s clinical system. Analyses were conducted using
multivariable logistic regression models adjusting for sociodemographic factors
(age bands, gender, IMD quintiles, and CCG). Univariable logistic regression
results were reported (<xref ref-type="supplementary-material" rid="sup1">Supplementary Table S7</xref>). An
exploratory analysis was conducted to identify the predictors of having a
registered mobile number. All results are presented using odds ratios (ORs),
95% confidence intervals (CIs), and <italic>P</italic>-values. <italic>P</italic>-values
&#x0003c;0.05 were considered as statistically significant.</p></sec></sec><sec><title>Results</title><sec><title>Population characteristics</title><p>In total, 8269 men and women were eligible for CRC screening and subsequently
invited to the NHS BCSP during the study identification period. Of these, 4135
were randomised to the control group and 4134 were randomised to the intervention
group. Baseline characteristics are shown in <xref rid="tbl1" ref-type="table">Table 1</xref>:
Individuals invited to screening had a median age of 66 (range 65&#x02013;69) years,
just over half were women (52.0%), and most had been invited to the NHS
BCSP more than once (81.4%). Less than one-tenth were from the least
deprived IMD quintile (8.6%), and about one-fifth were from the most
deprived IMD quintile (21.1%). The proportion of invitees was highest in
Croydon (21.7%), followed by Greenwich (20.7%), Hounslow
(19.9%), Lewisham (16.3%), and West London (14.5%) and lowest
in Hammersmith and Fulham (7.0%).</p></sec><sec><title>The impact of the intervention</title><p>Overall, 40.2% of individuals were adequately screened; there was no
significant difference in the proportion adequately screened between the
intervention (40.5%) and control groups (39.9% OR=1.03;
95% CI: 0.94&#x02013;1.12; <italic>P</italic>=0.56) (<xref rid="tbl2" ref-type="table">Table
2</xref>).</p></sec><sec><title>Factors associated with CRC screening uptake</title><p>CRC screening uptake was lower among men than women (37.4% <italic>vs</italic>
42.8% OR=0.80; 95% CI: 0.73&#x02013;0.88;
<italic>P</italic>=0.001), higher among people aged 70&#x02013;74 years than those
aged 60&#x02013;64 years (38.2% <italic>vs</italic> 42.8% OR=1.26;
95% CI: 1.11&#x02013;1.43; <italic>P</italic>&#x0003c;0.001), and lower among the most
deprived IMD quintile <italic>vs</italic> least deprived quintile (34.0%
<italic>vs</italic> 51.5% OR=0.53; 95% CI: 0.44&#x02013;0.64;
<italic>P</italic>&#x0003c;0.001). Uptake also varied significantly across the six London
CCGs (range from 30.5% to 47.1%). Having a registered mobile number
at the GP predicted greater uptake than not having a registered mobile number
43.6% <italic>vs</italic> 36.9% OR=1.31; 95% CI:
1.19&#x02013;1.44 <italic>P</italic>&#x0003c;0.001). Limiting the analysis to invitees with a
registered mobile who did not return their test kit by the eighth week also showed
no significant difference between the intervention (<italic>n</italic>=1393,
16.6%) and the control group (<italic>n</italic>=1346; 15.9%
OR=1.05; 95% CI: 0.85&#x02013;1.28&#x02013;1.52
<italic>P</italic>=0.67).</p></sec><sec><title>The impact on the intervention by invitation status</title><p>Although there was no main intervention effect, a test of interaction showed a
significant effect of the intervention according to invitation status
(<italic>P</italic>=0.02). There was a 5.6 percentage point difference between
uptake of the first-time invitees between the intervention (40.5%) and the
control groups (34.9% OR=1.29; 95% CI: 1.04&#x02013;1.58;
<italic>P</italic>=0.02) (<xref rid="tbl3" ref-type="table">Table 3</xref>). Among those who
had been previously invited to the screening programme at least once before this
study, there was no significant difference in uptake between the intervention
(41.1%) and the control group (40.5% OR=0.98; 95% CI:
0.89&#x02013;1.08, <italic>P</italic>=0.66). A further exploratory analysis showed no
effect of the intervention on uptake when stratified by IMD quintiles, age groups,
CCGs, or gender (<xref ref-type="supplementary-material" rid="sup1">Supplementary Table S5</xref>).</p></sec><sec><title>Mobile phone coverage and delivery of text-messages</title><p>Mobile phone coverage was assessed in the screening-eligible population. Coverage
varied according to age, gender, IMD score, and CCG (<xref rid="tbl4" ref-type="table">Table
4</xref>). Compared with those aged 60&#x02013;64 years, men and women aged
65&#x02013;69 years (OR=0.85; 95% CI: 0.77&#x02013;0.95;
<italic>P</italic>=0.004) and 70&#x02013;74 years (OR=0.67; 95% CI:
0.59&#x02013;0.75; <italic>P</italic>&#x0003c;0.001) were less likely to have a registered mobile
number. The proportion of people with a registered mobile number increased with
area-level deprivation, with mobile registration being 53.3% in the most
deprived IMD quintile, compared with 42.7% in the least deprived IMD
quintile (OR=1.67; 95% CI: 1.39&#x02013;2.02; <italic>P</italic>&#x0003c;0.001).
Mobile registration at GPs also varied by CCG. The largest proportion of
individuals with registered mobile phone numbers was observed at Croydon CCG,
where coverage was 61.9% (<italic>n</italic>=1109 out of 1791). The lowest
was observed in Hammersmith and Fulham CCG, where coverage was 32.2%
(<italic>n</italic>=186 out of 577; OR=0.29; 95% CI:
0.24&#x02013;0.36 <italic>P</italic>&#x0003c;0.001).</p><p>Despite differences in GP mobile phone registration, we found no statistically
significant difference in the successful delivery of text-messages by
participating CCG (<italic>P</italic>=0.08), age group (<italic>P</italic>=0.09),
gender (<italic>P</italic>=0.45), IMD quintile (<italic>P</italic>=0.41), or
invitation status (<italic>P</italic>=0.07). Among 1393 people in the intervention
group with a registered mobile and no returned kit, 73.4%
(<italic>n</italic>=1023) successfully received their reminders on the eighth week
of their screening episode. Further details of the delivery of text-messages can
be found in online <xref ref-type="supplementary-material" rid="sup1">Supplementary Materials</xref>
(<xref ref-type="supplementary-material" rid="sup1">Supplementary Table S6</xref>).</p></sec></sec><sec><title>Discussion</title><p>This trial examined the effectiveness of adding a text-message reminder to the
current NHS BCSP through the involvement of primary care. The primary analysis showed
that the intervention was not effective at improving uptake of adequate gFOBt
screening within six CCGs in London. Likewise, the secondary analysis, limited to
individuals who had not returned their test kit within 8 weeks and had a registered
mobile number at primary care, indicated that there was no significant difference
between the trial arms. However, the subgroup analysis showed that the intervention
increased uptake of gFOBt uptake among first-time invitees from 34.9% to
40.1%.</p><p>Overall, uptake within the six CCGs (Croydon, Greenwich, Hammersmith and Fulham,
Hounslow, Lewisham, West London) was 40.2%, which is consistent with uptake in
all of London (40.8%), reported for the first 2.6 million invitations in 2011
(<xref ref-type="bibr" rid="bib33">von Wagner <italic>et al</italic>, 2011</xref>). The social
gradient in uptake in this text-message reminder trial was consistent with the trends
in first-time and repeat CRC uptake, specifically with men consistently having lower
uptake than women, and people living in the most deprived areas of the six CCGs
having poorer uptake rates than those in the least deprived areas (<xref ref-type="bibr" rid="bib33">von Wagner <italic>et al</italic>, 2011</xref>; <xref ref-type="bibr" rid="bib19">Lo
<italic>et al</italic>, 2014</xref>; <xref ref-type="bibr" rid="bib23">Moss <italic>et al</italic>,
2016</xref>).</p><p>If CRC screening-eligible people complete their gFOBt test kit when they are first
invited, it is very likely that they will continue to do so following subsequent
invitations (<xref ref-type="bibr" rid="bib14">Janda <italic>et al</italic>, 2010</xref>; <xref ref-type="bibr" rid="bib21">Lo <italic>et al</italic>, 2015b</xref>). A previous study on repeat
screening participation over two rounds of screening invitations demonstrated that
while 86% of previous responders completed their second invitation, only
23% of the previous non-responders returned the test kit (<xref ref-type="bibr" rid="bib20">Lo <italic>et al</italic>, 2015a</xref>). Hence, the effect of this intervention on
the first-time invitees has important implications for the CRC screening uptake,
specifically to minimise practical barriers among individuals who have not engaged
with screening before their first invitation.</p><sec><title>Strengths and limitations</title><p>To our knowledge, this is the first large-scale trial examining the effectiveness
of text-message reminders in the context of gFOBT-based CRC screening in a
nationally organised programme. The trial was purposefully designed to test a
sustainable and a low cost (&#x0003c;&#x000a3;0.05 per text) alternative to postal
reminders (second Class UK postage=&#x000a3;0.55), with zero workload to GPs
and minimal opportunity costs to the NHS BCSP (<xref ref-type="bibr" rid="bib10">Hirst <italic>et
al</italic>, 2016</xref>). However, there may likely be a one-off investment
cost (e.g., change in IT infrastructure) to the NHS BCSP, if text-message
reminders were directly sent from the screening programme. Unlike an appointment
reminder, the text-message reminders in CRC screening will be limited to
non-responders, if applied within NHS BCSP. Unfortunately, possible inaccurate and
out-of-date mobile numbers and low proportions of people with registered mobile
phone numbers in primary care raise concerns that GP clinical records for mobile
phone numbers may not be up-to-date.</p><p>It is important to note a number of potential modifications, which could improve
the impact of the text-message reminder. In this study, the reminder was sent 8
weeks after the person was mailed their invitation. It is possible that at this
point many people would have already misplaced or thrown out their test kit.
Future research could test whether sending a text-message reminder earlier in the
episode could have more impact on uptake. Relatedly, previous studies that have
shown an effect of text-message reminders on CRC and breast screening uptake had
informed participants at the time of initial screening invitation that they may
receive a text-message reminder (<xref ref-type="bibr" rid="bib1">Baker <italic>et al</italic>,
2014</xref>; <xref ref-type="bibr" rid="bib17">Kerrison <italic>et al</italic>, 2015</xref>).
Sending a &#x02018;note&#x02019; at the start of the trial may act as a
&#x02018;primer&#x02019; and enhance the impact of a text-message reminder.</p></sec></sec><sec><title>Conclusion</title><p>GP-endorsed text-reminders at 8 weeks past the initial invitation of CRC screening
did not increase overall uptake in a socioeconomically deprived and ethnically
diverse areas in London but their positive impact on first-time invitees is promising
and could pay long-term dividends for the effectiveness of the programme.</p></sec></body><back><ack><p>We thank the London North West Healthcare NHS Trust for funding the trial, the Bowel
Cancer Screening London Hub and iPlato for facilitating the data collection during the
trial and NHS England London Region for their support during GP recruitment. YH is
supported by a Cancer Research UK programme grant awarded to Jane Wardle
(C1418/A14134). We also acknowledge the support from CCG cancer leads and Cancer
Research UK GP facilitators.</p></ack><fn-group><fn><p><xref ref-type="supplementary-material" rid="sup1">Supplementary Information</xref> accompanies this paper on
British Journal of Cancer website (http://www.nature.com/bjc)</p></fn><fn fn-type="COI-statement"><p>The authors declare no conflict of interest.</p></fn></fn-group><ref-list><ref id="bib1"><mixed-citation publication-type="journal">Baker DW, Brown T, Buchanan DR, Weil J, Balsley K, Ranalli L, Lee JY, Cameron KA, Ferreira MR, Stephens Q, Goldman SN (<year>2014</year>) <article-title>Comparative effectiveness of a multifaceted intervention to improve adherence to
annual colorectal cancer screening in community health centers: a randomized clinical
trial</article-title>. <source>JAMA Intern Med</source>
<volume>174</volume>(8): <fpage>1235</fpage>&#x02013;1241.<pub-id pub-id-type="pmid">24934845</pub-id></mixed-citation></ref><ref id="bib2"><mixed-citation publication-type="journal">Baron RC, Rimer BK, Breslow RA, Coates RJ, Kerner J, Melillo S, Habarta N, Kalra GP, Chattopadhyay S, Wilson KM, Lee NC (<year>2008</year>) <article-title>Client-directed interventions to increase community demand for breast, cervical,
and colorectal cancer screening: a systematic review</article-title>. <source>Am J Prev Med</source>
<volume>35</volume>(1): <fpage>S34</fpage>&#x02013;S55.<pub-id pub-id-type="pmid">18541187</pub-id></mixed-citation></ref><ref id="bib3"><mixed-citation publication-type="other">Cancer Research UK (<year>2016</year>)a <source>Bowel Cancer Incidence Statistics</source> Available at http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/bowel-cancer/incidence last accessed 8 November 2016.</mixed-citation></ref><ref id="bib4"><mixed-citation publication-type="other">Cancer Research UK (<year>2016</year>)b <source>Bowel Cancer Mortality Statistics</source> Available at http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/bowel-cancer/mortality last accessed 8 November 2016.</mixed-citation></ref><ref id="bib5"><mixed-citation publication-type="journal">Camilloni L, Ferroni E, Cendales BJ, Pezzarossi A, Furnari G, Borgia P, Guasticchi G, Rossi PG (<year>2013</year>) <article-title>Methods to increase participation in organised screening programs: a systematic
review</article-title>. <source>BMC Public Health</source>
<volume>13</volume>(1): <fpage>1</fpage>.<pub-id pub-id-type="pmid">23280303</pub-id></mixed-citation></ref><ref id="bib6"><mixed-citation publication-type="journal">Davis TC, Arnold CL, Bennett CL, Wolf MS, Reynolds C, Liu D, Rademaker A (<year>2014</year>) <article-title>Strategies to improve repeat fecal occult blood testing cancer
screening</article-title>. <source>Cancer Epidemiol Biomarkers Prev</source>
<volume>23</volume>(1): <fpage>134</fpage>&#x02013;143.<pub-id pub-id-type="pmid">24192009</pub-id></mixed-citation></ref><ref id="bib7"><mixed-citation publication-type="other">Gurol&#x02013;Urganci I, de Jongh T, Vodopivec&#x02013;Jamsek V, Atun R, Car J (<year>2013</year>) <article-title>Mobile phone messaging reminders for attendance at healthcare
appointments</article-title>. <source>Cochrane Database Syst Rev</source> (12): <fpage>CD007458</fpage>.<pub-id pub-id-type="pmid">24310741</pub-id></mixed-citation></ref><ref id="bib8"><mixed-citation publication-type="journal">Halloran SP (<year>2009</year>) <article-title>Bowel cancer screening</article-title>. <source>Surgery (Oxford)</source>
<volume>27</volume>(9): <fpage>397</fpage>&#x02013;400.</mixed-citation></ref><ref id="bib9"><mixed-citation publication-type="journal">Hewitson P, Glasziou P, Watson E, Towler B, Irwig L (<year>2008</year>) <article-title>Cochrane systematic review of colorectal cancer screening using the fecal occult
blood test (hemoccult): an update</article-title>. <source>Am J Gastroenterol</source>
<volume>103</volume>(6): <fpage>1541</fpage>&#x02013;1549.<pub-id pub-id-type="pmid">18479499</pub-id></mixed-citation></ref><ref id="bib10"><mixed-citation publication-type="journal">Hirst Y, Kerrison R, Kobayashi LC, Counsell N, Djedovic N, Ruwende J, Stewart M, von Wagner C (<year>2016</year>) <article-title>Text Reminders in Colorectal Cancer Screening (TRICCS): protocol for a
randomised controlled trial</article-title>. <source>BMC Public Health</source>
<volume>16</volume>(1): <fpage>74</fpage>.<pub-id pub-id-type="pmid">26809344</pub-id></mixed-citation></ref><ref id="bib11"><mixed-citation publication-type="other">House of Commons (<year>2014</year>) <source>Number of people who were eligible and who participated in the bowel cancer
screening programme &#x02014; England</source> Available at http://www.publications.parliament.uk/pa/cm201314/cmhansrd/cm140401/text/140401w0001.htm#1404026000191 (last accessed 8 November 2016).</mixed-citation></ref><ref id="bib12"><mixed-citation publication-type="journal">Icheku V, Arowobusoye N (<year>2015</year>) <article-title>Evaluation of a service intervention to improve uptake of breast cancer
screening in a London Borough with many hard to reach communities</article-title>. <source>Univ J Public Health</source>
<volume>3</volume>(2): <fpage>92</fpage>&#x02013;102.</mixed-citation></ref><ref id="bib13"><mixed-citation publication-type="other">iPlato (<year>2013</year>) <article-title>iPlato, about us 2013</article-title>. Available at http://www.iplato.net/about last accessed 9 November 2016.</mixed-citation></ref><ref id="bib14"><mixed-citation publication-type="journal">Janda M, Hughes KL, Auster JF, Leggett BA, Newman BM (<year>2010</year>) <article-title>Repeat participation in colorectal cancer screening utilizing fecal occult blood
testing: a community-based project in a rural setting</article-title>. <source>J Gastroenterol Hepatol</source>
<volume>25</volume>(10): <fpage>1661</fpage>&#x02013;1667.<pub-id pub-id-type="pmid">20880176</pub-id></mixed-citation></ref><ref id="bib15"><mixed-citation publication-type="journal">Janz NK, Lakhani I, Vijan S, Hawley ST, Chung LK, Katz SJ (<year>2007</year>) <article-title>Determinants of colorectal cancer screening use, attempts, and non-use</article-title>. <source>Prev Med</source>
<volume>44</volume>(5): <fpage>452</fpage>&#x02013;458.<pub-id pub-id-type="pmid">17196247</pub-id></mixed-citation></ref><ref id="bib16"><mixed-citation publication-type="journal">Kaplan WA (<year>2006</year>) <article-title>Can the ubiquitous power of mobile phones be used to improve health outcomes in
developing countries</article-title>? <source>Global Health</source>
<volume>2</volume>: <fpage>9</fpage>.<pub-id pub-id-type="pmid">16719925</pub-id></mixed-citation></ref><ref id="bib17"><mixed-citation publication-type="journal">Kerrison RS, Shukla H, Cunningham D, Oyebode O, Friedman E (<year>2015</year>) <article-title>Text-message reminders increase uptake of routine breast screening appointments:
a randomised controlled trial in a hard-to-reach population</article-title>. <source>BJC</source>
<volume>112</volume>(6): <fpage>1005</fpage>&#x02013;1010.<pub-id pub-id-type="pmid">25668008</pub-id></mixed-citation></ref><ref id="bib18"><mixed-citation publication-type="journal">Levin B, Lieberman DA, McFarland B, Smith RA, Brooks D, Andrews KS, Dash C, Giardiello FM, Glick S, Levin TR, Pickhardt P (<year>2008</year>) <article-title>Screening and surveillance for the early detection of colorectal cancer and
adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US
Multi&#x02013;Society Task Force on Colorectal Cancer, and the American College of
Radiology</article-title>. <source>CA Cancer J Clin</source>
<volume>58</volume>(3): <fpage>130</fpage>&#x02013;160.<pub-id pub-id-type="pmid">18322143</pub-id></mixed-citation></ref><ref id="bib19"><mixed-citation publication-type="journal">Lo SH, Halloran S, Snowball J, Seaman H, Wardle J, von Wagner C (<year>2014</year>) <article-title>Colorectal cancer screening uptake over three biennial invitation rounds in the
English bowel cancer screening programme</article-title>. <source>Gut</source>
<volume>64</volume>(2): <fpage>282</fpage>&#x02013;291.<pub-id pub-id-type="pmid">24812001</pub-id></mixed-citation></ref><ref id="bib20"><mixed-citation publication-type="journal">Lo SH, Halloran S, Snowball J, Seaman H, Wardle J, Von Wagner C (<year>2015</year>) a<article-title>Predictors of repeat participation in the NHS bowel cancer screening
programme</article-title>. <source>BJC</source>
<volume>112</volume>(1): <fpage>199</fpage>&#x02013;206.<pub-id pub-id-type="pmid">25429524</pub-id></mixed-citation></ref><ref id="bib21"><mixed-citation publication-type="journal">Lo SH, Waller J, Vrinten C, von Wagner C (<year>2015</year>) <article-title>Micro actions in colorectal cancer screening participation: a population-based
survey study</article-title>. <source>BMC Cancer</source>
<volume>15</volume>(1): <fpage>438</fpage>.<pub-id pub-id-type="pmid">26016989</pub-id></mixed-citation></ref><ref id="bib22"><mixed-citation publication-type="journal">Matsumoto M, Nishimura T (<year>1998</year>) <article-title>Mersenne twister: a 623-dimensionally equidistributed uniform pseudo-random
number generator</article-title>. <source>ACM Trans Model Comput Simul</source>
<volume>8</volume>: <fpage>3</fpage>&#x02013;30.</mixed-citation></ref><ref id="bib23"><mixed-citation publication-type="other">Moss S, Mathews C, Day TJ, Smith S, Seaman HE, Snowball J, Halloran SP (<year>2016</year>) <article-title>Increased uptake and improved outcomes of bowel cancer screening with a faecal
immunochemical test: results from a pilot study within the national screening
programme in England</article-title>. <source>Gut</source> e-pub ahead of print 7 June 2016; doi: 10.1136/gutjnl-2015-310691.</mixed-citation></ref><ref id="bib24"><mixed-citation publication-type="journal">Myers RE, Sifri R, Hyslop T, Rosenthal M, Vernon SW, Cocroft J, Wolf T, Andrel J, Wender R (<year>2007</year>) <article-title>A randomized controlled trial of the impact of targeted and tailored
interventions on colorectal cancer screening</article-title>. <source>Cancer</source>
<volume>110</volume>(9): <fpage>2083</fpage>&#x02013;2091.<pub-id pub-id-type="pmid">17893869</pub-id></mixed-citation></ref><ref id="bib25"><mixed-citation publication-type="other">Ofcom C (<year>2016</year>) <source>The Communications Market Reports</source> Available at http://stakeholders.ofcom.org.uk/binaries/research/cmr/cmr16/uk/CMR_UK_2016.pdf (last accessed 9 November 2016).</mixed-citation></ref><ref id="bib26"><mixed-citation publication-type="journal">Power E, Miles A, von Wagner C, Robb K, Wardle J (<year>2009</year>) <article-title>Uptake of colorectal cancer screening: system, provider and individual factors
and strategies to improve participation</article-title>. <source>Future Oncol</source>
<volume>5</volume>(9): <fpage>1371</fpage>&#x02013;1388.<pub-id pub-id-type="pmid">19903066</pub-id></mixed-citation></ref><ref id="bib27"><mixed-citation publication-type="journal">Scholefield JH, Moss S, Sufi F, Mangham CM, Hardcastle JD (<year>2002</year>) <article-title>Effect of faecal occult blood screening on mortality from colorectal cancer:
results from a randomised controlled trial</article-title>. <source>Gut</source>
<volume>50</volume>(6): <fpage>840</fpage>&#x02013;844.<pub-id pub-id-type="pmid">12010887</pub-id></mixed-citation></ref><ref id="bib28"><mixed-citation publication-type="book">Segnan N, Patnick J, Von Karsa L (Eds) (<year>2010</year>) <source>European Guidelines for Quality Assurance in Colorectal Cancer Screening and
Diagnosis</source>. Office for Official Publications of the European Communities: European
Commission.</mixed-citation></ref><ref id="bib29"><mixed-citation publication-type="journal">Senore C, Inadomi J, Segnan N, Bellisario C, Hassan C (<year>2015</year>) <article-title>Optimising colorectal cancer screening acceptance: a review</article-title>. <source>Gut</source>
<volume>64</volume>(7): <fpage>1158</fpage>&#x02013;1177.<pub-id pub-id-type="pmid">26059765</pub-id></mixed-citation></ref><ref id="bib30"><mixed-citation publication-type="journal">Sung JJ, Ng SC, Chan FK, Chiu HM, Kim HS, Matsuda T, Ng SS, Lau JY, Zheng S, Adler S, Reddy N (<year>2015</year>) <article-title>An updated Asia Pacific Consensus Recommendations on colorectal cancer
screening</article-title>. <source>Gut</source>
<volume>64</volume>(1): <fpage>121</fpage>&#x02013;132.<pub-id pub-id-type="pmid">24647008</pub-id></mixed-citation></ref><ref id="bib31"><mixed-citation publication-type="journal">van Dam L, Korfage IJ, Kuipers EJ, Hol L, van Roon AH, Reijerink JC, van Ballegooijen M, van Leerdam ME (<year>2013</year>) <article-title>What influences the decision to participate in colorectal cancer screening with
faecal occult blood testing and sigmoidoscopy</article-title>? <source>Eur J Cancer</source>
<volume>49</volume>(10): <fpage>2321</fpage>&#x02013;2330.<pub-id pub-id-type="pmid">23571149</pub-id></mixed-citation></ref><ref id="bib32"><mixed-citation publication-type="journal">van Rijn AF, van Rossum LG, Deutekom M, Laheij RJ, Fockens P, Bossuyt PM, Dekker E, Jansen JB (<year>2008</year>) <article-title>Low priority main reason not to participate in a colorectal cancer screening
program with a faecal occult blood test</article-title>. <source>J Public Health (Oxf)</source>
<volume>30</volume>(4): <fpage>461</fpage>&#x02013;465.<pub-id pub-id-type="pmid">18716047</pub-id></mixed-citation></ref><ref id="bib33"><mixed-citation publication-type="journal">von Wagner C, Baio G, Raine R, Snowball J, Morris S, Atkin W, Obichere A, Handley G, Logan RF, Rainbow S, Smith S, Halloran S, Wardle J (<year>2011</year>) <article-title>Inequalities in participation in an organized national colorectal cancer
screening programme: results from the first 2.6 million invitations in
England</article-title>. <source>Int J Epidemiol</source>
<volume>40</volume>(3): <fpage>712</fpage>&#x02013;718.<pub-id pub-id-type="pmid">21330344</pub-id></mixed-citation></ref><ref id="bib34"><mixed-citation publication-type="journal">White B, Power E, Ciurej M, Lo SH, Nash K, Ormiston-Smith N (<year>2015</year>) <article-title>Piloting the impact of three interventions on guaiac faecal occult blood test
uptake within the NHS Bowel Cancer Screening Programme</article-title>. <source>Biomed Res Int</source>
<volume>2015</volume>: <fpage>928251</fpage>.<pub-id pub-id-type="pmid">26525423</pub-id></mixed-citation></ref></ref-list><sec sec-type="supplementary-material" id="sup1"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="xob1"><label>Supplementary Table S5</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bjc2017117x1.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="xob2"><label>Supplementary Table S6</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bjc2017117x2.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="xob3"><label>Supplementary Table S7</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bjc2017117x3.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></back><floats-group><fig id="fig1"><label>Figure 1</label><caption><p>
<bold>Study consort diagram.</bold>
</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bjc2017117f1"/></fig><table-wrap id="tbl1"><label>Table 1</label><caption><title>Sample characteristics</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="char" char="("/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th align="center" valign="top" char="(" charoff="50"><bold>% (</bold><italic><bold>n</bold></italic>)</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">Overall</td><td align="char" valign="top" char="(" charoff="50">100 (<italic>n</italic>=8269)</td></tr><tr><td align="left" valign="top" charoff="50">Age, years</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;60&#x02013;64</td><td align="char" valign="top" char="(" charoff="50">44.5 (3682)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;65&#x02013;69</td><td align="char" valign="top" char="(" charoff="50">29.8 (2466)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;70&#x02013;74</td><td align="char" valign="top" char="(" charoff="50">25.7 (2121)</td></tr><tr><td align="left" valign="top" charoff="50">Gender</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Male</td><td align="char" valign="top" char="(" charoff="50">48.0 (3973)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Female</td><td align="char" valign="top" char="(" charoff="50">52.0 (4296)</td></tr><tr><td align="left" valign="top" charoff="50">Index of Multiple Deprivation</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Quintile 1 (least deprived)</td><td align="char" valign="top" char="(" charoff="50">8.6 (705)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Quintile 2</td><td align="char" valign="top" char="(" charoff="50">14.1 (1157)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Quintile 3</td><td align="char" valign="top" char="(" charoff="50">25.0 (2044)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Quintile 4</td><td align="char" valign="top" char="(" charoff="50">31.1 (2544)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Quintile 5 (most deprived)</td><td align="char" valign="top" char="(" charoff="50">21.1 (1727)</td></tr><tr><td align="left" valign="top" charoff="50">Clinical Commissioning Group</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Croydon</td><td align="char" valign="top" char="(" charoff="50">21.7 (1791)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Greenwich</td><td align="char" valign="top" char="(" charoff="50">20.7 (1712)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Hammersmith and Fulham</td><td align="char" valign="top" char="(" charoff="50">7.0 (577)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Hounslow</td><td align="char" valign="top" char="(" charoff="50">19.9 (1645)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Lewisham</td><td align="char" valign="top" char="(" charoff="50">16.3 (1349)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;West London</td><td align="char" valign="top" char="(" charoff="50">14.5 (1195)</td></tr><tr><td align="left" valign="top" charoff="50">Invitation status</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;First-time invitees</td><td align="char" valign="top" char="(" charoff="50">18.6 (1542)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Repeat invitees</td><td align="char" valign="top" char="(" charoff="50">81.4 (6727)</td></tr></tbody></table></table-wrap><table-wrap id="tbl2"><label>Table 2</label><caption><title>Intention to treat and secondary analysis</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="char" char="("/><col align="char" char="("/><col align="char" char="."/><col align="char" char="("/><col align="char" char="("/><col align="char" char="."/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th colspan="2" align="center" valign="top" char="(" charoff="50">
<bold>Intention-to-treat (</bold>
<italic>
<bold>N</bold>
</italic>
<bold>=8269)</bold>
<hr/></th><th align="char" valign="top" char="." charoff="50">&#x000a0;</th><th colspan="2" align="center" valign="top" char="(" charoff="50">
<bold>Secondary analysis (</bold>
<italic>
<bold>N</bold>
</italic>
<bold>=2739)</bold>
<hr/></th><th align="char" valign="top" char="." charoff="50">&#x000a0;</th></tr><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th align="center" valign="top" char="(" charoff="50"><bold>% uptake (</bold><italic><bold>N</bold></italic>)</th><th align="center" valign="top" char="(" charoff="50">
<bold>OR (95% CI)</bold>
</th><th align="center" valign="top" char="." charoff="50">
<italic>
<bold>P</bold>
</italic>
<bold>-value</bold>
</th><th align="center" valign="top" char="(" charoff="50"><bold>% uptake (</bold><italic><bold>N</bold></italic>)</th><th align="center" valign="top" char="(" charoff="50">
<bold>OR (95% CI)</bold>
</th><th align="center" valign="top" char="." charoff="50">
<italic>
<bold>P</bold>
</italic>
<bold>-value</bold>
</th></tr></thead><tbody valign="top"><tr><td colspan="7" align="left" valign="top" charoff="50">
<bold>Study group</bold>
<hr/></td></tr><tr><td align="left" valign="top" charoff="50">Control</td><td align="char" valign="top" char="(" charoff="50">39.9 (1648)</td><td align="center" valign="top" char="(" charoff="50">Ref.</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">15.9 (214)</td><td align="center" valign="top" char="(" charoff="50">Ref.</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">Intervention</td><td align="char" valign="top" char="(" charoff="50">40.5 (1674)</td><td align="char" valign="top" char="(" charoff="50">1.03 (0.94&#x02013;1.12)</td><td align="char" valign="top" char="." charoff="50">0.560</td><td align="char" valign="top" char="(" charoff="50">16.6 (231)</td><td align="char" valign="top" char="(" charoff="50">1.05 (0.85&#x02013;1.28)</td><td align="char" valign="top" char="." charoff="50">0.670</td></tr><tr><td colspan="7" align="left" valign="top" charoff="50">
<bold>Gender</bold>
<hr/></td></tr><tr><td align="left" valign="top" charoff="50">Female</td><td align="char" valign="top" char="(" charoff="50">42.8 (1837)</td><td align="center" valign="top" char="(" charoff="50">Ref.</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">16.1 (224)</td><td align="center" valign="top" char="(" charoff="50">Ref.</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">Male</td><td align="char" valign="top" char="(" charoff="50">37.4 (1485)</td><td align="char" valign="top" char="(" charoff="50">0.80 (0.73&#x02013;0.88)</td><td align="char" valign="top" char="." charoff="50">0.001</td><td align="char" valign="top" char="(" charoff="50">16.4 (221)</td><td align="char" valign="top" char="(" charoff="50">0.97 (0.79&#x02013;1.19)</td><td align="char" valign="top" char="." charoff="50">0.750</td></tr><tr><td colspan="7" align="left" valign="top" charoff="50">
<bold>Age, years</bold>
<hr/></td></tr><tr><td align="left" valign="top" charoff="50">60&#x02013;64</td><td align="char" valign="top" char="(" charoff="50">38.2 (1407)</td><td align="center" valign="top" char="(" charoff="50">Ref.</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">16.7 (233)</td><td align="center" valign="top" char="(" charoff="50">Ref.</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">65&#x02013;69</td><td align="char" valign="top" char="(" charoff="50">40.9 (1008)</td><td align="char" valign="top" char="(" charoff="50">1.13 (1.00&#x02013;1.27)</td><td align="char" valign="top" char="." charoff="50">0.050</td><td align="char" valign="top" char="(" charoff="50">16.9 (132)</td><td align="char" valign="top" char="(" charoff="50">1.14 (0.87&#x02013;1.49)</td><td align="char" valign="top" char="." charoff="50">0.340</td></tr><tr><td align="left" valign="top" charoff="50">70&#x02013;74</td><td align="char" valign="top" char="(" charoff="50">42.8 (907)</td><td align="char" valign="top" char="(" charoff="50">1.26 (1.11&#x02013;1.43)</td><td align="char" valign="top" char="." charoff="50">0.000</td><td align="char" valign="top" char="(" charoff="50">14.2 (80)</td><td align="char" valign="top" char="(" charoff="50">0.97 (0.72&#x02013;1.33)</td><td align="char" valign="top" char="." charoff="50">0.870</td></tr><tr><td colspan="7" align="left" valign="top" charoff="50">
<bold>Index of Multiple Deprivation</bold>
<hr/></td></tr><tr><td align="left" valign="top" charoff="50">Quintile 1 (least deprived)</td><td align="char" valign="top" char="(" charoff="50">51.5 (363)</td><td align="center" valign="top" char="(" charoff="50">Ref.</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">26.4 (178)</td><td align="center" valign="top" char="(" charoff="50">Ref.</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">Quintile 2</td><td align="char" valign="top" char="(" charoff="50">41.9 (485)</td><td align="char" valign="top" char="(" charoff="50">0.79 (0.65&#x02013;0.95)</td><td align="char" valign="top" char="." charoff="50">0.003</td><td align="char" valign="top" char="(" charoff="50">23.4 (71)</td><td align="char" valign="top" char="(" charoff="50">0.93 (0.59&#x02013;1.44)</td><td align="char" valign="top" char="." charoff="50">0.740</td></tr><tr><td align="left" valign="top" charoff="50">Quintile 3</td><td align="char" valign="top" char="(" charoff="50">43.4 (888)</td><td align="char" valign="top" char="(" charoff="50">0.77 (0.64&#x02013;0.95)</td><td align="char" valign="top" char="." charoff="50">0.000</td><td align="char" valign="top" char="(" charoff="50">17.4 (113)</td><td align="char" valign="top" char="(" charoff="50">0.62 (0.41&#x02013;0.92)</td><td align="char" valign="top" char="." charoff="50">0.020</td></tr><tr><td align="left" valign="top" charoff="50">Quintile 4</td><td align="char" valign="top" char="(" charoff="50">38.0 (967)</td><td align="char" valign="top" char="(" charoff="50">0.61 (0.51&#x02013;0.73)</td><td align="char" valign="top" char="." charoff="50">0.000</td><td align="char" valign="top" char="(" charoff="50">15.0 (137)</td><td align="char" valign="top" char="(" charoff="50">0.52 (0.35&#x02013;0.76)</td><td align="char" valign="top" char="." charoff="50">0.001</td></tr><tr><td align="left" valign="top" charoff="50">Quintile 5 (most deprived)</td><td align="char" valign="top" char="(" charoff="50">34.0 (587)</td><td align="char" valign="top" char="(" charoff="50">0.53 (0.44&#x02013;0.64)</td><td align="char" valign="top" char="." charoff="50">0.000</td><td align="char" valign="top" char="(" charoff="50">11.0 (72)</td><td align="char" valign="top" char="(" charoff="50">0.38 (0.26&#x02013;0.57)</td><td align="char" valign="top" char="." charoff="50">0.000</td></tr><tr><td colspan="7" align="left" valign="top" charoff="50">
<bold>Clinical Commissioning Groups</bold>
<hr/></td></tr><tr><td align="left" valign="top" charoff="50">Croydon</td><td align="char" valign="top" char="(" charoff="50">47.1 (843)</td><td align="center" valign="top" char="(" charoff="50">Ref.</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">18.5 (129)</td><td align="center" valign="top" char="(" charoff="50">Ref.</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">Greenwich</td><td align="char" valign="top" char="(" charoff="50">43.3 (742)</td><td align="char" valign="top" char="(" charoff="50">0.89 (0.77&#x02013;1.01)</td><td align="char" valign="top" char="." charoff="50">0.080</td><td align="char" valign="top" char="(" charoff="50">17.0 (109)</td><td align="char" valign="top" char="(" charoff="50">0.93 (0.69&#x02013;1.25)</td><td align="char" valign="top" char="." charoff="50">0.640</td></tr><tr><td align="left" valign="top" charoff="50">Hammersmith and Fulham</td><td align="char" valign="top" char="(" charoff="50">35.9 (207)</td><td align="char" valign="top" char="(" charoff="50">0.68 (0.56&#x02013;0.83)</td><td align="char" valign="top" char="." charoff="50">0.000</td><td align="char" valign="top" char="(" charoff="50">14.2 (18)</td><td align="char" valign="top" char="(" charoff="50">0.75 (0.44&#x02013;1.29)</td><td align="char" valign="top" char="." charoff="50">0.290</td></tr><tr><td align="left" valign="top" charoff="50">Hounslow</td><td align="char" valign="top" char="(" charoff="50">40.1 (660)</td><td align="char" valign="top" char="(" charoff="50">0.77 (0.67&#x02013;0.89)</td><td align="char" valign="top" char="." charoff="50">0.000</td><td align="char" valign="top" char="(" charoff="50">18.6 (73)</td><td align="char" valign="top" char="(" charoff="50">0.95 (0.68&#x02013;1.33)</td><td align="char" valign="top" char="." charoff="50">0.780</td></tr><tr><td align="left" valign="top" charoff="50">Lewisham</td><td align="char" valign="top" char="(" charoff="50">37.5 (506)</td><td align="char" valign="top" char="(" charoff="50">0.73(0.63&#x02013;0.85)</td><td align="char" valign="top" char="." charoff="50">0.000</td><td align="char" valign="top" char="(" charoff="50">13.8 (77)</td><td align="char" valign="top" char="(" charoff="50">0.79 (0.58&#x02013;1.09)</td><td align="char" valign="top" char="." charoff="50">0.160</td></tr><tr><td align="left" valign="top" charoff="50">West London</td><td align="char" valign="top" char="(" charoff="50">30.5 (364)</td><td align="char" valign="top" char="(" charoff="50">0.56 (0.47&#x02013;0.65)</td><td align="char" valign="top" char="." charoff="50">0.000</td><td align="char" valign="top" char="(" charoff="50">12.0 (39)</td><td align="char" valign="top" char="(" charoff="50">0.65 (0.43&#x02013;0.96)</td><td align="char" valign="top" char="." charoff="50">0.030</td></tr><tr><td colspan="7" align="left" valign="top" charoff="50">
<bold>Invitation status</bold>
<hr/></td></tr><tr><td align="left" valign="top" charoff="50">First-time invitee</td><td align="char" valign="top" char="(" charoff="50">37.5 (579)</td><td align="center" valign="top" char="(" charoff="50">Ref.</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">18.9 (117)</td><td align="center" valign="top" char="(" charoff="50">Ref.</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">Repeat invitee</td><td align="char" valign="top" char="(" charoff="50">40.8 (2743)</td><td align="char" valign="top" char="(" charoff="50">1.01 (0.89&#x02013;1.16)</td><td align="char" valign="top" char="." charoff="50">0.870</td><td align="char" valign="top" char="(" charoff="50">15.5 (328)</td><td align="char" valign="top" char="(" charoff="50">0.74 (0.56&#x02013;0.98)</td><td align="char" valign="top" char="." charoff="50">0.040</td></tr><tr><td colspan="7" align="left" valign="top" charoff="50">
<bold>Registered mobile number</bold>
<hr/></td></tr><tr><td align="left" valign="top" charoff="50">No</td><td align="char" valign="top" char="(" charoff="50">36.9 (1541)</td><td align="center" valign="top" char="(" charoff="50">Ref.</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="center" valign="top" char="(" charoff="50">NA</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">Yes</td><td align="char" valign="top" char="(" charoff="50">43.6 (1781)</td><td align="char" valign="top" char="(" charoff="50">1.31 (1.19&#x02013;1.44)</td><td align="char" valign="top" char="." charoff="50">0.000</td><td align="center" valign="top" char="(" charoff="50">NA</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr></tbody></table><table-wrap-foot><fn id="t2-fn1"><p>Abbreviations: CI=confidence interval; NA=not applicable;
OR=odds ratio.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl3"><label>Table 3</label><caption><title>Impact of the intervention by invitation status</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="char" char="("/><col align="char" char="("/><col align="char" char="("/><col align="char" char="."/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th align="center" valign="top" char="(" charoff="50">
<bold>Control (</bold>
<italic>
<bold>n</bold>
</italic>
<bold>=4135)</bold>
<xref ref-type="fn" rid="t3-fn2">a</xref>
</th><th align="center" valign="top" char="(" charoff="50">
<bold>Intervention (</bold>
<italic>
<bold>n</bold>
</italic>
<bold>=4134)</bold>
</th><th align="char" valign="top" char="(" charoff="50">&#x000a0;</th><th align="char" valign="top" char="." charoff="50">&#x000a0;</th></tr><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th align="center" valign="top" char="(" charoff="50"><bold>% (</bold><italic><bold>N</bold></italic>)</th><th align="center" valign="top" char="(" charoff="50"><bold>% (</bold><italic><bold>N</bold></italic>)</th><th align="center" valign="top" char="(" charoff="50">
<bold>OR (95% CI)</bold>
</th><th align="center" valign="top" char="." charoff="50">
<italic>
<bold>P</bold>
</italic>
<bold>-value</bold>
</th></tr></thead><tbody valign="top"><tr><td colspan="5" align="left" valign="top" charoff="50">
<bold>Invitation status</bold>
<hr/></td></tr><tr><td align="left" valign="top" charoff="50">First-time invitee</td><td align="char" valign="top" char="(" charoff="50">34.9 (282)</td><td align="char" valign="top" char="(" charoff="50">40.5 (297)</td><td align="char" valign="top" char="(" charoff="50">1.29 (1.04&#x02013;1.58)</td><td align="char" valign="top" char="." charoff="50">0.02</td></tr><tr><td align="left" valign="top" charoff="50">Repeat invitee</td><td align="char" valign="top" char="(" charoff="50">41.1 (1366)</td><td align="char" valign="top" char="(" charoff="50">40.5 (1377)</td><td align="char" valign="top" char="(" charoff="50">0.98 (89&#x02013;1.08)</td><td align="char" valign="top" char="." charoff="50">0.66</td></tr></tbody></table><table-wrap-foot><fn id="t3-fn1"><p>Abbreviations: CI=confidence interval; OR=odds ratio.</p></fn><fn id="t3-fn2"><label>a</label><p>Reference group (adjusted for age, gender, Index of Multiple Deprivation,
and Clinical Commissioning Group).</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl4"><label>Table 4</label><caption><title>Mobile phone coverage in London among 141 general practices</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="char" char="("/><col align="char" char="("/><col align="char" char="."/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th align="center" valign="top" char="(" charoff="50"><bold>% (</bold><italic><bold>N</bold></italic>)</th><th align="center" valign="top" char="(" charoff="50">
<bold>OR (95% CI)</bold>
</th><th align="center" valign="top" char="." charoff="50">
<italic>
<bold>P</bold>
</italic>
<bold>-value</bold>
</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">Overall</td><td align="char" valign="top" char="(" charoff="50">49.4 (<italic>N</italic>=4089)</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">By gender</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Female</td><td align="char" valign="top" char="(" charoff="50">48.4 (<italic>n</italic>=2079)</td><td align="center" valign="top" char="(" charoff="50">Ref.</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Male</td><td align="char" valign="top" char="(" charoff="50">50.6 (<italic>n</italic>=2010)</td><td align="char" valign="top" char="(" charoff="50">1.08 (0.99&#x02013;1.18)</td><td align="char" valign="top" char="." charoff="50">0.09</td></tr><tr><td align="left" valign="top" charoff="50">By age (years)</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;60&#x02013;64</td><td align="char" valign="top" char="(" charoff="50">53.6 (<italic>n</italic>=1972)</td><td align="center" valign="top" char="(" charoff="50">Ref.</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;65&#x02013;69</td><td align="char" valign="top" char="(" charoff="50">49.2 (<italic>n</italic>=1213)</td><td align="char" valign="top" char="(" charoff="50">0.85 (0.77&#x02013;0.95)</td><td align="char" valign="top" char="." charoff="50">0.004</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;70&#x02013;74</td><td align="char" valign="top" char="(" charoff="50">42.6 (<italic>n</italic>=904)</td><td align="char" valign="top" char="(" charoff="50">0.67 (0.59&#x02013;0.75)</td><td align="char" valign="top" char="." charoff="50">&#x0003c;0.001</td></tr><tr><td align="left" valign="top" charoff="50">By IMD</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Quintile 1 (least deprived)</td><td align="char" valign="top" char="(" charoff="50">42.7 (<italic>n</italic>=301)</td><td align="center" valign="top" char="(" charoff="50">Ref.</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Quintile 2</td><td align="char" valign="top" char="(" charoff="50">40.7 (<italic>n</italic>=471)</td><td align="char" valign="top" char="(" charoff="50">1.24 (1.01&#x02013;1.51)</td><td align="char" valign="top" char="." charoff="50">0.04</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Quintile 3</td><td align="char" valign="top" char="(" charoff="50">50.2 (<italic>n</italic>=1026)</td><td align="char" valign="top" char="(" charoff="50">1.61 (1.34&#x02013;1.93)</td><td align="char" valign="top" char="." charoff="50">&#x0003c;0.001</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Quintile 4</td><td align="char" valign="top" char="(" charoff="50">51.7 (<italic>n</italic>=1316)</td><td align="char" valign="top" char="(" charoff="50">1.62 (1.36&#x02013;1.94)</td><td align="char" valign="top" char="." charoff="50">&#x0003c;0.001</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Quintile 5 (most deprived)</td><td align="char" valign="top" char="(" charoff="50">53.3 (<italic>n</italic>=920)</td><td align="char" valign="top" char="(" charoff="50">1.67 (1.39&#x02013;2.02)</td><td align="char" valign="top" char="." charoff="50">&#x0003c;0.001</td></tr><tr><td align="left" valign="top" charoff="50">By CCG</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Croydon</td><td align="char" valign="top" char="(" charoff="50">61.9 (<italic>n</italic>=1109)</td><td align="center" valign="top" char="(" charoff="50">Ref.</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Greenwich</td><td align="char" valign="top" char="(" charoff="50">56.1 (<italic>n</italic>=960)</td><td align="char" valign="top" char="(" charoff="50">0.79 (0.68&#x02013;0.90)</td><td align="char" valign="top" char="." charoff="50">0.001</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Hammersmith and Fulham</td><td align="char" valign="top" char="(" charoff="50">32.2 (<italic>n</italic>=186)</td><td align="char" valign="top" char="(" charoff="50">0.29 (0.24&#x02013;0.36)</td><td align="char" valign="top" char="." charoff="50">&#x0003c;0.001</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Hounslow</td><td align="char" valign="top" char="(" charoff="50">36.2 (<italic>n</italic>=595)</td><td align="char" valign="top" char="(" charoff="50">0.35 (0.30&#x02013;0.41)</td><td align="char" valign="top" char="." charoff="50">&#x0003c;0.001</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Lewisham</td><td align="char" valign="top" char="(" charoff="50">58.1 (<italic>n</italic>=784)</td><td align="char" valign="top" char="(" charoff="50">0.81 (0.70&#x02013;0.95)</td><td align="char" valign="top" char="." charoff="50">0.007</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;West London</td><td align="char" valign="top" char="(" charoff="50">38.1 (<italic>n</italic>=455)</td><td align="char" valign="top" char="(" charoff="50">0.38 (0.32&#x02013;0.44)</td><td align="char" valign="top" char="." charoff="50">&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><fn id="t4-fn1"><p>Abbreviations: CCG=Clinical Commissioning Group; CI=confidence
interval; IMD=Index of Multiple Deprivation; OR=odds
ratio.</p></fn></table-wrap-foot></table-wrap></floats-group></article>